Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, Hofmann F, Roberts CW, Graus Porta D.

PLoS One. 2013 Oct 30;8(10):e77652. doi: 10.1371/journal.pone.0077652. eCollection 2013.

2.

SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.

Wei D, Goldfarb D, Song S, Cannon C, Yan F, Sakellariou-Thompson D, Emanuele M, Major MB, Weissman BE, Kuwahara Y.

Mol Cancer Res. 2014 Nov;12(11):1574-85. doi: 10.1158/1541-7786.MCR-14-0005. Epub 2014 Jul 9.

3.

SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.

Kuwahara Y, Wei D, Durand J, Weissman BE.

Mol Cancer Res. 2013 Mar;11(3):251-60. doi: 10.1158/1541-7786.MCR-12-0390. Epub 2013 Jan 30.

4.

The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.

Caramel J, Medjkane S, Quignon F, Delattre O.

Oncogene. 2008 Mar 27;27(14):2035-44. Epub 2007 Oct 8.

PMID:
17922027
5.

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M.

Nat Med. 2010 Dec;16(12):1429-33. doi: 10.1038/nm.2251. Epub 2010 Nov 14.

6.

Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.

Darr J, Klochendler A, Isaac S, Eden A.

Oncogene. 2014 Jun 5;33(23):3024-32. doi: 10.1038/onc.2013.261. Epub 2013 Jul 15.

PMID:
23851500
7.

Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

McKenna ES, Tamayo P, Cho YJ, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CW.

Cell Cycle. 2012 May 15;11(10):1956-65. doi: 10.4161/cc.20280. Epub 2012 May 15.

8.

Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.

Lee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV.

Cancer Res. 2011 May 1;71(9):3225-35. doi: 10.1158/0008-5472.CAN-10-2167. Epub 2011 Apr 26.

9.

Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA, Ekert PG, Saffery R, Craig J, Johnstone RW, Ashley DM.

PLoS One. 2009;4(2):e4482. doi: 10.1371/journal.pone.0004482. Epub 2009 Feb 16.

10.

Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.

Darr J, Klochendler A, Isaac S, Geiger T, Eden A.

Mol Cancer. 2015 Sep 15;14:167. doi: 10.1186/s12943-015-0439-5. Erratum in: Mol Cancer. 2016;15:14. Geiger, Tami [Corrected to Geiger, Tamar].

11.

Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.

Kim KH, Roberts CW.

Cancer Genet. 2014 Sep;207(9):365-72. doi: 10.1016/j.cancergen.2014.04.004. Epub 2014 Apr 13. Review.

12.

SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.

Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP.

Mol Cell Biol. 2008 May;28(10):3457-64. doi: 10.1128/MCB.02019-07. Epub 2008 Mar 10.

13.

Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.

Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy SL, Mesirov JP, Roberts CW.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50. Epub 2005 Nov 21.

14.

Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.

Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, Roberts CW.

Cancer Res. 2009 Oct 15;69(20):8094-101. doi: 10.1158/0008-5472.CAN-09-0733. Epub 2009 Sep 29.

15.

Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.

Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH.

Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800.

16.

Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.

Rao Q, Xia QY, Wang ZY, Li L, Shen Q, Shi SS, Wang X, Liu B, Wang YF, Shi QL, Ma HH, Lu ZF, He Y, Zhang RS, Yu B, Zhou XJ.

Histopathology. 2015 Jul;67(1):121-9. doi: 10.1111/his.12632. Epub 2015 Feb 5.

PMID:
25496315
17.

P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.

Oruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LM, Mohd-Sarip A, Vries RG, Hoeben RC, Verrijzer CP.

J Biol Chem. 2004 Jan 30;279(5):3807-16. Epub 2003 Nov 6.

18.

Chromatin remodeling: from transcription to cancer.

Yaniv M.

Cancer Genet. 2014 Sep;207(9):352-7. doi: 10.1016/j.cancergen.2014.03.006. Epub 2014 Mar 22. Review.

PMID:
24825771
19.
20.

Pathology and diagnosis of SMARCB1-deficient tumors.

Margol AS, Judkins AR.

Cancer Genet. 2014 Sep;207(9):358-64. doi: 10.1016/j.cancergen.2014.07.004. Epub 2014 Aug 1. Review.

PMID:
25246033
Items per page

Supplemental Content

Write to the Help Desk